Odomzo (Sonidegib Phosphate) Patent Expiration, LOE Window & CMS Spending

Odomzo (Sonidegib Phosphate) by Sun Pharmaceutical: FDA Orange Book core substance LOE 2036-03-30, 0 AB generics, $52.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSun Pharmaceutical
FDA Application & PathwayN205266 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-03-30
Last Listed Patent or Exclusivity Date2036-03-30
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$52.0M
2024 Medicare Part D Spend$46.0M
2024 Medicaid Spend$5.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel